recombinant human somatotropin

PreclinicalSmall molecule

recombinant human somatotropin is one of 8 small molecule programs targeting Hypoparathyroidism. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypoparathyroidismActive, not recruiting

HypoparathyroidismPreclinical

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Hypoparathyroidism

#DrugCompanyPhaseTrials

Theo-Dur

Pfizer

Approved

2 2

Rocaltrol

Calciferol

Calcium

1 5

EXT608

EExtend Biosciences Inc.

Phase 2

1 6

Intravenous Injection of 68ga-PMD22

PPeking Union Medical College Hospital

Phase 1

1 7

Yorvipath

Ascendis Pharma

Preclinical

2 8

recombinant human somatotropin

UUniversity of Milan

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypoparathyroidism1 trial

Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)

Unknown status·UUniversity of Milan·N/A·NCT00497484

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for recombinant human somatotropin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — recombinant human somatotropin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for recombinant human somatotropin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Milan company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Milan

recombinant human somatotropin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypoparathyroidism1 trial

References

Drug Info

Quick Facts

Related News